Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI)

Historical Holders from Q1 2025 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
KPTI on Nasdaq
Shares outstanding
13,264,980
Price per share
$6.54
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
2,947,949
Total reported value
$19,279,960
% of total 13F portfolios
0%
Share change
-1,407,244
Value change
-$7,678,884
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
51
Price from insider filings
$6.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
T. Rowe Price Investment Management, Inc. 14% +68% $15,073,429 +$10,306,134 2,304,242 +216% T. Rowe Price Investment Management, Inc. 31 Oct 2025
Opaleye Management Inc. 9.5% $10,262,842 1,569,002 Opaleye Management Inc. 10 Oct 2025
J. WOOD CAPITAL ADVISORS LLC 5% $6,546,231 1,000,708 J. Wood Capital Advisors LLC 14 Oct 2025
Affinity Asset Advisors, LLC 7.8% $2,849,521 664,224 Affinity Healthcare Fund, LP 03 Apr 2025
HIGHBRIDGE CAPITAL MANAGEMENT LLC 4.9% $4,251,935 649,984 HIGHBRIDGE CAPITAL MANAGEMENT, LLC 30 Sep 2025
JPMORGAN CHASE & CO 4.9% -6% $2,797,089 -$149,213 427,624 -5.1% JPMORGAN CHASE & CO. 30 Sep 2025
VANGUARD GROUP INC 4.7% $2,670,221 408,222 The Vanguard Group 30 Sep 2025
As of 30 Sep 2025, Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 51 institutional shareholders filing 13F forms. They hold 2,947,949 shares. of 13,264,980 outstanding shares (22%) .

Top 25 institutional shareholders own 22% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
T. Rowe Price Investment Management, Inc. 5.3% 700,992 -3.8% 0% $4,585,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 3.2% 421,322 0% 0% $2,755,446
VANGUARD GROUP INC 3.1% 408,222 -21% 0% $2,669,772
BlackRock, Inc. 1.7% 231,951 -2% 0% $1,516,959
Catalio Capital Management, LP 1.1% 142,984 -2.1% 0.17% $935,115
Avidity Partners Management LP 1% 134,566 0% 0.2% $880,062
MARSHALL WACE, LLP 0.97% 128,451 0% 0% $840,070
C WorldWide Group Holding A/S 0.75% 100,000 0% 0.01% $654,000
GEODE CAPITAL MANAGEMENT, LLC 0.7% 93,289 +1.6% 0% $610,250
GROUP ONE TRADING LLC 0.52% 68,436 -30% 0.01% $447,571
RENAISSANCE TECHNOLOGIES LLC 0.49% 64,714 -1.7% 0% $423,230
UBS Group AG 0.45% 59,685 -63% 0% $390,340
STATE STREET CORP 0.35% 46,342 +39% 0% $303,077
SILVERBACK ASSET MANAGEMENT LLC 0.3% 40,000 -43% 0.03% $261,600
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.27% 35,339 0% $231,117
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.26% 34,873 -7.8% 0% $228,069
Ikarian Capital, LLC 0.21% 27,257 0% 0.04% $178,261
Baird Financial Group, Inc. 0.2% 25,932 +146% 0% $169,595
MORGAN STANLEY 0.19% 25,766 +2.7% 0% $168,509
ADAR1 Capital Management, LLC 0.19% 25,000 0.02% $163,500
GOLDMAN SACHS GROUP INC 0.19% 24,885 -77% 0% $162,748
NORTHERN TRUST CORP 0.14% 18,876 -0.18% 0% $123,449
Belvedere Trading LLC 0.11% 14,563 0.01% $95,242
XTX Topco Ltd 0.11% 14,402 +10% 0% $94,189
GSA CAPITAL PARTNERS LLP 0.11% 14,076 +1.3% 0.01% $92,000

Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 2,947,949 $19,279,960 -$7,678,884 654% 51
2025 Q2 4,384,748 $18,898,424 +$4,718,117 431% 49
2025 Q1 3,312,096 $12,386,145 +$12,277,831 374% 46